(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical company, reported its third-quarter 2025 financial results and highlighted the upcoming events to watch in the coming months.
The company's lead drug candidate is Ozekibart (INBRX-109), a multivalent therapeutic candidate being developed for the treatment of chondrosarcoma, colorectal cancer and Ewing sarcoma.
In a Phase 3 pivotal study, the results of which were announced in October of this year, a statistically significant and clinically meaningful improvement in median progression-free survival was observed in the ozekibart arm compared to placebo. Key secondary endpoints reinforced the benefit, showing improvements in disease control and patient quality of life.
Inhibrx is planning to submit a Biologics License Application (BLA) to the U.S. FDA in the second quarter of 2026 for ozekibart in chondrosarcoma, following positive pivotal trial results.
Ozekibart is also being tested in a phase I trial in subjects with locally advanced or metastatic solid tumors Including sarcomas.
According to the results announced last month, interim data from expansion cohorts in patients with colorectal cancer and Ewing sarcoma in the phase 1 trial demonstrated high response and disease control rates in difficult-to-treat, heavily pretreated patients.
In addition to ozekibart, Inhibrx is advancing INBRX-106, a multivalent therapeutic candidate designed as an immune agonist with optimized valency to enhance T-cell activation.
INBRX-106 is being evaluated in the following clinical trials.
-- A phase II/III study of INBRX-106 combined with Merck's Keytruda against Keytruda alone as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma expressing PD-L1, dubbed HexAgon-HN.
-- A phase I/II study of INBRX-106 in combination with Keytruda in patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma.
Net loss was $35.3 million, or $2.28 per share, in Q3, 2025, compared to a net loss of $43.9 million, or $2.84 per share, in the prior-year quarter.
Inhibrx reported cash and cash equivalents of $153.1 million as of September 30, 2025.
INBX has traded in the range of $10.81 to $86.64 over the past year. The stock closed Friday (November 14, 2025) at $79.13, up 6.04%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
